- Home
- BCRX vs JANX Comparison
BCRX vs JANX Comparison
Compare BCRX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCRX | JANX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCRX | JANX |
|---|---|---|
| Price | $7.40 | $14.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $20.08 | ★ $60.27 |
| AVG Volume (30 Days) | ★ 3.5M | 2.3M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $599,816,000.00 | $10,000,000.00 |
| Revenue This Year | $39.98 | N/A |
| Revenue Next Year | $7.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.38 | N/A |
| 52 Week Low | $6.00 | $13.26 |
| 52 Week High | $11.31 | $56.89 |
Technical Indicators
Market Signals| Indicator | BCRX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 32.46 |
| Support Level | $7.52 | $13.26 |
| Resistance Level | $8.05 | $14.30 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | -0.01 | 0.47 |
| Stochastic Oscillator | 40.12 | 61.29 |
Price Performance
Historical ComparisonAbout BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.